Metastatic Pancreatic Ductal Adenocarcinoma

Oncology·MeSH: Pancreatic Neoplasms

17 drugs in development·14 companies·13 clinical trials

Drug Pipeline by Phase

Phase 3(2)

Drug	Company
nis793	Novartis AG (NVS)
Olaparib	Merck & Co., Inc. (MRK)

Phase 2(4)

Drug	Company
BXCL701	BioXcel Therapeutics, Inc. (BTAI)
BXCL701	Merck & Co., Inc. (MRK)
lsta1	LISATA THERAPEUTICS, INC. (LSTA)
nuzefatide pevedotin	BICYCLE THERAPEUTICS PLC (BCYC)

Phase 1(10)

Drug	Company
68ga-dfc413	Novartis AG (NVS)
68ga-nns309	Novartis AG (NVS)
Botensilimab	AGENUS INC (AGEN)
Emavusertib	Amneal Pharmaceuticals, Inc. (AMRX)
mFOLFIRINOX	Aclaris Therapeutics, Inc. (ACRS)
ONT01	ENANTA PHARMACEUTICALS INC (ENTA)
Quemliclustat	Arcus Biosciences, Inc. (RCUS)
Zunsemetinib	KYNTRA BIO INC. (KYNB)
Zunsemetinib	Merus N.V. (MRUS)
Zunsemetinib	Tango Therapeutics, Inc. (TNGX)

Phase 2/Phase 3(1)

Drug	Company
folinic acid/ leucovorina	AbbVie Inc. (ABBV)

BioSniper tracks 17 drugs in development for Metastatic Pancreatic Ductal Adenocarcinoma across 14 companies.

There are 13 clinical trials targeting Metastatic Pancreatic Ductal Adenocarcinoma tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.